1. Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study. (6th August 2019) Authors: Chen, Zhanhong; Zheng, Yabing; Cao, Wenming; Zhang, Yuzi; Zhao, Zhengyi; Wang, Guoqiang; Zhao, Jing; Cai, Shangli; Shao, Xiying; Huang, Jian; Ye, Weiwu; Huang, Yuan; Li, Wei; Huang, Xiang; Wu, Hao; Wang, Xiaojia; Yin, Yongmei Journal: Cancer medicine Issue: Volume 8:Number 12(2019:Sep.) Page Start: 5544 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Facing the CDK4/6i resistance dilemma in patients with breast cancer, exploration of the resistance mechanism and possible reverse strategy: A narrative review. Issue 51 (23rd December 2022) Authors: Wu, Jiayi; Wang, Wei; Shao, Xiying; Lin, Guang; Wang, Xiaojia Journal: Medicine Issue: Volume 101:Issue 51(2022) Page Start: e32238 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. (2nd January 2016) Authors: Xiao, Peng; Wan, Xiaopeng; Cui, Bijun; Liu, Yang; Qiu, Chenyang; Rong, Jiabing; Zheng, Mingzhu; Song, Yinjing; Chen, Luoquan; He, Jia; Tan, Qinchun; Wang, Xiaojia; Shao, Xiying; Liu, Yuhua; Cao, Xuetao; Wang, Qingqing Journal: Oncoimmunology Issue: Volume 5:Number 1(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Issue 2 (23rd December 2019) Authors: Chen, Zhanhong; Sun, Tian; Yang, Ziyan; Zheng, Yabing; Yu, Ruoying; Wu, Xue; Yan, Junrong; Shao, Yang W; Shao, Xiying; Cao, Wenming; Wang, Xiaojia Journal: Molecular genetics & genomic medicine Issue: Volume 8:Issue 2(2020) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗